Giovedì 14 Novembre 2024, ore 13
Edificio Asclepio U8-Aula 2
► Diretta webex
Alzheimer’s disease (AD) is a debilitating, chronic, insidious, and progressive neurodegenerative condition of old age, and has a long preclinical period of approximately 20 years.
Approximately 50 million people worldwide are living with Alzheimer’s disease or other dementias, with numbers expected to reach 82 million by 2030 and 152 million by 2050.
Drug repurposing involves seeking new indications or molecular targets different from a drug’s known activity, pharmacological effects, or binding specificities. Given the increasing rates of drug failures in clinical trials, drug repositioning has emerged as a promising strategy to mitigate the risk of such failures. Drugs that are already FDA-approved to treat diseases other than dementia may hold a key to effectively treating Alzheimer’s and related disorders. Researchers are exploring multiple ways to repurpose drugs either alone or in combination with another therapeutic.
This lecture will focus on the progress made in drug repurposing for AD throughout the last decade, summarizing the suggested drug candidates and analyzing changes in the repurposing strategies used over time.
Nesrine Salah El Dine El Sayed
Prof. Nesrine Salah El Dine is a professor and head of pharmacology and toxicology department, Faculty of Pharmacy, Cairo University. In addition, she is the director of the International Relations Bureau in the faculty.
Her research interest is focused on the molecular mechanisms underlying the signaling pathways of many neurodegenerative diseases. She has a high record of publications (80 publications) in highly impact international journals, H index 25. She served as a referee and editorial board member for many international organizations and scientific journals as well as evaluation of many national and international projects.
She is the PI of many projects and actively participated in more than 20 international conferences worldwide.
She is a member of many national and international societies and associations; the German Neuroscience Society, the European Behavioral Pharmacology Society, the American Heart Association the International Pharmaceutical Federation (FIP).
She is the academic coordinator of the mobility agreement under the framework of Erasmus+ KA107 between Cairo University and Medical University in Lublin-Poland (2019-2022, 2022-2025) and Milano- Bicocca University in Milan, Italy (2024-2026), as well as the Erasmus mobility KA171 and MoU between Cairo University and Saarland University in Homburg, Germany (2022-2025).
She is invited as speaker in many events in different universities in many countries e.g. Saarland university in Germany, Alexandru Ioan Cuza University in Romania, Aristotle university in Greece, Medical University of Lublin in Poland.